Kolkata, 10 March 2026: Medtronic, a global leader in healthcare technology, and the Institute of Neurosciences Kolkata (I-NK) today announced a partnership to promote and support medical professionals through enhanced skill development and exposure to the latest technologies in the field of neuromodulation. These efforts will also include raising awareness and disseminating information about available therapy options for the management of Parkinson’s disease and other movement disorders to clinicians and patients, ensuring well-informed care pathways.
Parkinson’s disease (PD) in East India, particularly in cities like Kolkata, shows a prevalence of approximately 45.82 per 100,000 people, with a high incidence of early-onset cases (before age 50)1. Parkinson’s disease is a progressive neurological condition that can significantly impact movement, daily functioning, and quality of life2. Neuromodulation therapies, including deep brain stimulation (DBS), have emerged as an option for appropriately selected patients, helping to improve motor symptoms. Recent advances such as adaptive Deep Brain Stimulation (aDBS), which dynamically adjust stimulation based on patient-specific neural signals, represent an evolving area of innovation aimed at more personalized therapy. Through this collaboration, Medtronic and I-NK aim to strengthen education, training, and awareness initiatives to support clinicians, patients, and caregivers in understanding the role of advanced neuromodulation therapies such as Deep Brain Stimulation (DBS) for Parkinson’s, Dystonia, Tremor and other movement disorders, Spinal Cord Stimulation (SCS) and Targeted Drug Delivery (TDD) for chronic neuropathic pain, and Sacral Neuromodulation (SNM) for bladder and bowel incontinence.
Medtronic has been a pioneer in neuromodulation therapies, with over 50 years of experience in advancing therapies for conditions such as Parkinson’s, dystonia, tremors and other movement disorders. By collaborating with I-NK, a recognized Center of Excellence Medtronic is committed toward expanding access to evidence-based neuromodulation therapies and increasing awareness about their potential benefits for patients living with these conditions.
Commenting on the partnership, Mandeep Singh Kumar, Managing Director & Vice President, Medtronic India said, “Neuromodulation care demands a high degree of clinical precision alongside well-informed patient engagement. Through our collaboration with Institute of Neurosciences Kolkata, we are committed to building structured and sustainable clinical capabilities in West Bengal, beginning with Kolkata. I am confident that this partnership will meaningfully advance the treatment of Parkinson’s disease and deliver long-term benefits to patients’’.
INK, a single specialty hospital dedicated to neurology, neurosurgery, psychiatry, and related disciplines, has recently enhanced its capabilities by acquiring advanced Microelectrode Recording (MER) technology, enabling greater precision and confidence in neuromodulation procedures, particularly in movement disorder surgeries.As a Center of Excellence, I-NK plays an important role in promoting best practices in Parkinson’s, Dystonia, Tremor and other movement disorder care training healthcare professionals and contributing to the broader neuromodulation ecosystem in India. In addition, I-NK’s role as a research center supports clinical studies, innovation, and knowledge generation in neuromodulation, contributing to the continuous evolution of Parkinson’s disease care.
Commenting on the initiative, Dr. Hrishikesh Kumar, Vice Chairman and Head of Neurology Department, Director of Movement Disorders program at Institute of Neurosciences Kolkata said, “As neuromodulation becomes an important part of neurological care, there is a growing need for clarity both among clinicians and patients around therapy pathways and decision-making. With Medtronic’s pioneering legacy in neuromodulation and I-NK’s enhanced capabilities, including advanced state- of-the -art facilities, we aim to educate, increase awareness, improve clinical confidence, and support the appropriate adoption of neuromodulation therapies for patients who can benefit the most. This initiative allows us to focus on knowledge-sharing and training in a structured manner which is essential for long-term patient care.” Dr. Bibhukalyani Das, Dr. Jacky Ganguly, Dr. Amit Kumar Ghosh, and Dr. Supriyo Choudhury emphasized the need for a Centre of Excellence for neuromodulation in this region.
With India having a much higher burden of Parkinson’s due to its large population3., this timely initiative underscores Medtronic’s dedication to advancing healthcare outcomes, supporting the strategic growth of India’s healthcare ecosystem, and ultimately transforming patient lives
For further information, please contact:
Medtronic
Nidhi Acharya
nidhi.acharya@medtronic.com
All information contained herein is for general awareness purposes only, and nothing contained herein should be construed as medical advice or recommendation. Patients should consult their physician to discuss their conditions and seek relevant medical advice.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.
Reference:
1. Surathi P, Jhunjhunwala K, Yadav R, Pal PK. Research in Parkinson’s disease in India: A review. Ann Indian Acad Neurol. 2016 Jan-Mar;19(1):9-20. doi: 10.4103/0972-2327.167713. PMID: 27011622; PMCID: PMC4782561.
2. Zafar S, Lui F, Yaddanapudi SS. Parkinson Disease. [Updated 2025 Sep 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470193/
3. 3. Surathi P, Jhunjhunwala K, Yadav R, Pal PK. Research in Parkinson’s disease in India: A review. Ann Indian Acad Neurol. 2016 Jan-Mar;19(1):9-20. doi: 10.4103/0972-2327.167713. PMID: 27011622; PMCID: PMC4782561.
